Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MetFlex: trimetazidine in ALS/MND
NL-OMON52162Phase 2Active, not recruiting
- Sponsor
- The University of Queensland
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trimetazidine in amyotrophic lateral sclerosis (ALS) and motor neuron disease (MND), sponsored by The University of Queensland. Primary endpoints: Safety and tolerability of trimetazidine and Change from baseline in oxidative stress markers. Started Oct 2021; status: active, not recruiting.
02
Drugs
trimetazidine
03
Conditions
amyotrophic lateral sclerosis (ALS)motor neuron disease (MND)
Beyond the preview
Go deeper on NL-OMON52162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52162.